Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sutro Biopharma (STRO) Accumulated Depreciation & Amortization (2017 - 2025)

Sutro Biopharma's Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $48.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 15.34% year-over-year to $48.6 million; the TTM value through Dec 2024 reached $48.6 million, up 15.34%, while the annual FY2024 figure was $48.6 million, 15.34% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $48.6 million at Sutro Biopharma, up from $42.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $48.6 million in Q4 2024 and bottomed at $33.4 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $37.9 million (2022), against an average of $39.8 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization fell 9.24% in 2021 before it grew 15.34% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $36.8 million in 2020, then decreased by 9.24% to $33.4 million in 2021, then grew by 13.4% to $37.9 million in 2022, then grew by 11.23% to $42.2 million in 2023, then grew by 15.34% to $48.6 million in 2024.
  • Per Business Quant, the three most recent readings for STRO's Accumulated Depreciation & Amortization are $48.6 million (Q4 2024), $42.2 million (Q4 2023), and $37.9 million (Q4 2022).